Gina Columbus

Arlene O. Siefker-Radtke, MD, discusses the exciting advances in the bladder cancer field, why researchers should move past PD-L1 as a biomarker, and what combinations can be expected to move through the pipeline next.

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.

John C. Araujo, MD, PhD, discusses targeted therapies, current and emerging, for patients with bone-metastatic castration-resistant prostate cancer.

Eric Jonasch, MD, speaks on the evolving choices for patients with renal cell carcinoma in the first- and second-line settings, as well as the remaining challenges in the field.

Ramesh K. Ramanathan, MD, discusses emerging agents and the hurdles oncologists are facing in the field of pancreatic cancer.

Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.

Rahmi Oklu, MD, PhD, discusses various approaches physicians use to treat patients who have CRC with liver metastases.

Lewis R. Roberts, MB, ChB, PhD, spoke on the current state of hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses updates in the gastric cancer landscape, biomarker developments, and agents emerging in the pipeline.

Axel Grothey, MD, discusses frontline therapy and maintenance strategies for patients with metastatic colorectal cancer.

Evidence continues to build for the long-term efficacy of PD-1-targeting immunotherapies in melanoma, including fresh data indicating when patients can stop taking the drugs and still maintain a response.

Andre Goy, MD, discusses combination regimens and other developments in the evolving treatment landscape in mantle cell lymphoma.

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

Joyce A. O’Shaughnessy, MD, addresses the key issues in breast cancer discussed at the 2017 OncLive® State of the Science Summit on Treatment of Metastatic Breast Cancer and shared her expert insight on where triple-negative breast cancer treatment is headed based on recent findings.

Melanie E. Royce, MD, PhD, discusses the recent progress in the landscape of HER2-positive breast cancer and what she envisions future treatment approaches will be for patients.

Henry M. Kuerer, MD, PhD, discusses surgical advancements in the field of breast cancer and the goals of a phase II single-center trial and how it could impact these exceptional responders.

Welela Tereffe, MD, discusses the current state of radiation therapy in breast cancer and the importance of a multidisciplinary approach.

Jenny C. Chang, MD, discusses the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.

The fields of mantle cell lymphoma and diffuse large B-cell lymphoma had a handful of updates presented during the 2016 ASH Annual Meeting.

Emerging therapies in myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and myelofibrosis could have the potential to shake up the landscape.

Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin to improve outcomes for these patients.

A combination regimen of the BCL-2 inhibitor venetoclax plus low-dose cytarabine demonstrated an acceptable safety and pharmacokinetic profile in elderly patients with treatment-naïve acute myeloid leukemia.

Novel therapies are being investigated in 2 areas of hematologic malignancies, but the first-line setting is where the brunt of research needs to be conducted.

The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.

The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.